11 December 2020: Original Paper
Outcomes of Non-Cryopreserved Versus Cryopreserved Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma
Pokpong Piriyakhuntorn ABCDE* , Adisak Tantiworawit AE , Thanawat Rattanathammethee E , Sasinee Hantrakool E , Chatree Chai-Adisaksopha E , Ekarat Rattarittamrong E , Lalita Norasetthada EDOI: 10.12659/AOT.927084
Ann Transplant 2020; 25:e927084
Table 2 Transplant-related outcomes.
| Outcomes | Non-cryopreserved (N=26) | Cryopreserved (N=16) | P-value |
|---|---|---|---|
| Time to neutrophil engraftment (days) – median (range) | 12 (10–19) | 10.5 (8–20) | 0.203 |
| Time to platelet engraftment (days) – median (range) | 14 (10–23) | 12 (10–31) | 0.809 |
| Incidence of graft failure – no. (%) | 0 | 0 | 1.000 |
| Transplant-related mortality – no. (%) | 1 (3.8) | 0 | 0.619 |
| CD34 cell dose (×10/kg) – median (range) | 3.8 (2.0–16.5) | 4.7 (2.3–29.1) | 0.062 |
| CD34 cell viability (%) – median (range) | 98.5 (94–99) | 93.5 (70–98) | |
| Infusion-related AEs – no. (%) | 5 (19.2) | 6 (37.5) | 0.172 |
| Infectious complications – no. (%) | 0.765 | ||
| Fever of unknown origin | 14 (53.8) | 9 (56.2) | |
| Microbiologically documented infection | 6 (23.1) | 2 (12.5) | |
| Clinically documented infection | 6 (23.1) | 5 (31.3) | |
| Duration of hospitalization (days) – median (range) | |||
| Entire cohort | 25.5 (18–30) | 33 (17–55) | 0.002 |
| Only G-CSF mobilization | 25.5 (18–30) | 32 (17–50) | 0.064 |
| Total cost of ASCT (in 1,000 USD) – mean±SD | |||
| Entire cohort | 10.6±2.4 | 11.8±5.1 | 0.314 |
| Only G-CSF mobilization | 10.6±2.4 | 12.6±5.8 | 0.288 |
| Only first ASCT | 10.6±2.4 | 12.9±3.5 | 0.026 |
| AE – adverse event; ASCT – autologous stem cell transplantation; G-CSF – granulocyte colony stimulating factor. | |||